|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
6/10/2010 11:53:25 AM
BLOOMINGTON, Ind. -- Indiana University and the Ohio State University will receive $9 million from the National Cancer Institute to continue studying cancer genes and the sometimes-unnatural agents that mask the genes' expression, a phenomenon called epigenetics.
The National Cancer Institute is a division of the National Institutes of Health.
OSU School of Medicine cancer geneticist Timothy Huang and IU School of Medicine cancer biologist Kenneth Nephew co-administer the OSU-IU Center for Cancer Systems Biology and its project, "Interrogating Epigenetic Changes in Cancer Genomes," which began in 2004 with about $8 million in NCI support. Ten other centers received funding or continued funding this year as part of the NCI's Integrative Cancer Biology Program.
"Our group uses integrated computational and experimental approaches to study epigenetic mechanisms that control signaling networks in prostate, breast, and ovarian cancers," said Nephew, a member of the IU School of Medicine's Bloomington faculty. "During the initial funding period, we focused on epigenetic processes associated with neoplastic transformation of normal cells into cancer cells. We demonstrated that disruption of key networks contribute to the development of breast, prostate, and ovarian cancer, and we developed mathematical models based on our experimental data."
Over the next five years, Nephew said the OSU/IU-led team will study epigenetic changes in prostate, breast, and ovarian cancer cells that cause resistance to hormonal therapy or traditional chemotherapy. Nephew said a major objective is to identify a panel of epigenetic biomarkers for predicting responsiveness to anti-hormone treatments and chemotherapies in cancer patients.
"These centers represent a unique multidisciplinary union of outstanding scientists and clinicians who will work to unravel the complexities of cancer through the novel application of technology and mathematical modeling," said Dan Gallahan, NCI Integrative Cancer Biology Program director. "Their discoveries and models will be critical to our continued success in understanding and treating this disease."
The OSU-IU center also has an "Education Core," which is training young scientists to conduct integrated cancer research. During the initial funding period, the OSU-IU center hosted 14 summer programs and co-organized two systems biology meetings. Center staff trained 137 undergraduate, graduate, and post-graduate students and supported the activities of more than a dozen short- and long-term visitors.
|
|
|
|
|
|
|
|
|
|
|